Heart Disease
MAb Used in Percutaneous Coronary Revascularization
Published in Monoclonal Antibodies Weekly, February 2nd, 2000
"Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa," wrote C. J. Dunn and colleagues of Adis International Ltd, New Zealand. "The drug is used in conjunction with heparin and aspirin to prevent ischemic complications associated with percutaneous coronary revascularization in patients with coronary heart disease."
Dunn et al. published their study in Pharmacoeconomics ("Abciximab - a pharmacoeconomic review of its use in percutaneous coronary revascularization,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly
More Articles from Monoclonal Antibodies Weekly
- Antibody Therapy
Anticancer Strategy Redirects Natural Antibodies To New Target - Cancer Gene Therapy
Antibody Targeting Facilitates Gene Transfer to RCC Cells - Pathogenesis
CD44S Expression Correlates with Renal Clear Cell Carcinoma - Vascular Tumors (Pathogenesis)
Lack of Lymphatic Vascular Specificity of VEGFR-3 Found - Antigen-Specific Therapy
WT1 Is Target for Adoptive Immunotherapy of Leukemia - B-Chronic Lymphocyte Leukemia
CD4+ Cells Found Circulating in B-CLL Patients - More from this issue of Monoclonal Antibodies Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
